var data={"title":"Spironolactone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Spironolactone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6984?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=spironolactone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Spironolactone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=spironolactone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Spironolactone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709416\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Tumorigenic: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats. Use spironolactone only in those conditions for which it is indicated. Avoid unnecessary use of this drug.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222861\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aldactone;</li>\n      <li>CaroSpir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222862\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aldactone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222908\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Diuretic, Potassium Sparing;</li>\n      <li>\n        Mineralocorticoid (Aldosterone) Receptor Antagonists</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222866\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Suspension is <b>NOT</b> therapeutically equivalent to tablets. In patients requiring &gt;100 mg/dose, use tablets (&gt;100 mg/dose of suspension may result in spironolactone concentration higher than expected).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Oral: 25 to 200 mg daily in single or divided doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Initial: 75 mg daily in single or divided doses. Titrate slowly. When used as the sole agent for diuresis, administer &ge;5 days before increasing dose to obtain desired effect.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Severe (NYHA class III to IV):</b> Oral: Initial: 12.5 to 25 mg once daily; maximum: 50 mg/day. If 25 mg once daily not tolerated, may reduce to 25 mg every other day (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>NYHA class II; LVEF &le;35% (off-label use): </b>Oral: 12.5 to 25 mg once daily; maximum: 50 mg/day (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Post myocardial infarction; LVEF &le;40% (off-label use):</b> Oral: 12.5 to 25 mg once daily; maximum: 50 mg/day (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Per the manufacturer, if potassium &gt;5 mEq/L or serum creatinine &gt;4 mg/dL, discontinue or interrupt therapy. Alternatively, the ACCF/AHA 2013 HF guidelines recommend withholding treatment if potassium &gt;5.5 mEq/L or renal function worsens; hold doses until potassium is &lt;5 mEq/L and consider restarting with a reduced dose after confirming resolution of hyperkalemia/renal insufficiency for at least 72 hours (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Serum potassium &le;5 mEq/L: Initial: 20 mg once daily. May titrate to 37.5 mg once daily or decrease to 20 mg every other day as clinically indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypokalemia:</b> Oral: Tablet: 25 to 100 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral: Initial:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: 50 to 100 mg in single or divided doses; after 2 weeks, may adjust dose. In patients with resistant hypertension, an initial daily dose of 25 mg may also be added to other antihypertensive agents with an increase to 50 mg daily if needed (Vaclavik 2014; Williams 2015). Usual dosage range (ASH/ISH [Weber 2014]): 25 to 50 mg daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: 20 to 75 mg daily in single or divided doses; may titrate at 2-week intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary</b>\n      <b> aldosteronism: </b>Oral: Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Diagnostic aid:</i> Long test: 400 mg once daily for 3 to 4 weeks; short test: 400 mg once daily for 4 days <b>Note</b>: Clinical practice guidelines recommend using the plasma aldosterone/renin ratio (ARR) to detect potential cases of primary aldosteronism (not spironolactone); in addition, spironolactone (a mineralocorticoid receptor antagonist) should be withdrawn at least 4 weeks before ARR testing for optimal test interpretation (Funder 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance until surgical correction: </i>100 to 400 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Treatment of bilateral adrenal hypersecretion, or unilateral hypersecretion in patients unwilling or unable to undergo surgery:</i> Initial: 12.5 to 25 mg once daily; gradually titrate upward if necessary to the lowest effective dose (maximum: 100 mg/day) (Funder 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acne vulgaris (females) (off-label use):</b> Oral: 50 to 200 mg once daily (AAD [Zaenglein 2016]; Goodfellow 1984; Muhlemann 1986)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ascites, due to cirrhosis (off-label dose):</b> Initial: 100 mg once daily; titrate every 3 to 5 days as clinically indicated (usual maximum: 400 mg once daily); a spironolactone to furosemide dosing ratio of 100 mg (spironolactone) to 40 mg (furosemide) should be maintained (AASLD [Runyon 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hirsutism in women (off-label use):</b> Oral: 50 to 200 mg daily in 1 to 2 divided doses (Koulouri 2008; Martin 2008)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222886\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=spironolactone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Spironolactone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema, hypertension (off-label use):</b> Oral: Children and Adolescents: Initial: 1 mg/kg/day divided every 12 to 24 hours (maximum dose: 3.3 mg/kg/day, up to 100 mg daily) (NHBPEP 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222867\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">\n      <b>Hypertension:</b> Oral: No initial dosage adjustment necessary (Aronow 2011).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222868\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Manufacturer's labeling:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Contraindicated in patients with anuria, acute renal impairment, or significant impairment of renal excretory function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Edema, hypertension: </i>There are no dosage adjustments provided in the manufacturer's labeling; spironolactone is substantially excreted by the kidney; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Heart failure:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR 30 to 50 mL/minute/1.73 m<sup>2</sup>: Initial: 10 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no specific dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Alternate recommendations:</b> Tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Heart failure (ACCF/AHA [Yancy 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR &ge;50 mL/minute/1.73 m<sup>2</sup>: Initial dose: 12.5 to 25 mg once daily; Maintenance dose (after 4 weeks of treatment with potassium &le;5 mEq/L): 25 mg once or twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR 30 to 49 mL/minute/1.73 m<sup>2</sup>: Initial dose: 12.5 mg once daily or every other day; Maintenance dose (after 4 weeks of treatment with potassium &le;5 mEq/L): 12.5 to 25 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">eGFR &lt;30 mL/minute/1.73 m<sup>2</sup>: Not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patients &ge;65 years: CrCl &lt;30 mL/minute (regardless of indication): Avoid use due to risk of hyperkalemia (Beers Criteria [AGS 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21885517\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling. Use with caution; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222835\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CaroSpir: 25 mg/5 mL (118 mL, 473 mL) [contains saccharin sodium; banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aldactone: 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aldactone: 50 mg, 100 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 25 mg, 50 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222819\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50591704\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Solution: Shake well before administering dose. Administer with or without food; however, administer consistently with respect to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132823\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends single gloving for administration of intact tablets or capsules. If manipulating tablets/capsules (eg, to prepare an oral suspension), NIOSH recommends double gloving, a protective gown, and preparation in a controlled device; if not prepared in a controlled device, respiratory and eye/face protection as well as ventilated engineering controls are recommended. NIOSH recommends double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection for administration of an oral liquid/feeding tube administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222838\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Edema:</b> Management of edema and sodium retention associated with heart failure unresponsive to other therapies; cirrhosis of liver accompanied by edema and/or ascites; or nephrotic syndrome unresponsive to other therapies.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b> Heart failure, severe: </b>To increase survival and to reduce hospitalization for severe heart failure (New York Heart Association class III to IV) when used in addition to standard therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations: </i>The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 2013 heart failure guidelines recommend the use of aldosterone antagonists, along with other guideline-directed medical therapies, to reduce morbidity and mortality in patients with heart failure (New York Heart Association [NYHA] class III to IV) with left ventricular ejection fraction (LVEF) 35% or less.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension: </b>Management of hypertension unresponsive to other therapies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Guideline recommendations:</i> According to the Eighth Joint National Committee (JNC 8) guidelines, aldosterone antagonists are not recommended for the initial treatment of hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypokalemia (tablet only):</b> Treatment of hypokalemia unresponsive to other therapies; prophylaxis of hypokalemia in patients taking digitalis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary hyperaldosteronism (tablet only): </b>Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial; short-term preoperative treatment of primary hyperaldosteronism; long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery; long-term maintenance therapy for bilateral micro- or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25471214\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acne vulgaris (females); Heart failure (NYHA class II; LVEF &le;35%); Heart failure (post-myocardial infarction; LVEF &le;40%):; Hirsutism; Hypertension, diuretic (pediatric); Post-myocardial infarction (left ventricular ejection fraction &le;40%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222916\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aldactone may be confused with Aldactazide</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Spironolactone should be avoided in patients 65 years and older with creatinine clearance &lt;30 mL/minute due to risk of hyperkalemia (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aldactone: Brand name for spironolactone [US, Canada, multiple international markets], but also the brand name for potassium canrenoate [Austria, Czech Republic, Germany, Hungary, Poland]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aldactone  [US, Canada, multiple international markets] may be confused with Aldomet brand name for methyldopa [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222826\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Gynecomastia (9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia, confusion, dizziness, drowsiness, headache, lethargy, nipple pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia, chloasma, erythematous maculopapular rash, pruritus, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Amenorrhea, decreased libido, electrolyte disturbance, hyperkalemia, hyponatremia, hypovolemia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, diarrhea, gastritis, gastrointestinal hemorrhage, gastrointestinal ulcer, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction, impotence, irregular menses, mastalgia, postmenopausal bleeding</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Agranulocytosis, leukopenia, malignant neoplasm of breast, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Hepatotoxicity</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: DRESS syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Leg cramps</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen, renal failure, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222842\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyperkalemia; Addison disease; concomitant use with eplerenone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications: Tablet only: Anuria; acute renal insufficiency; significant impairment of renal excretory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Hypersensitivity to spironolactone or any component of the formulation; concomitant use with heparin or low molecular weight heparin; pregnancy; breastfeeding.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222823\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid/electrolyte imbalance: Fluid and electrolyte imbalance (eg, hypomagnesemia, hyponatremia, hypocalcemia, hypochloremic alkalosis, hyperglycemia, hyperkalemia, acidosis, elevated BUN) may occur; close medical supervision and dose evaluation are required. Patients with heart failure, renal disease, or cirrhosis may be particularly susceptible. Monitor and correct electrolyte disturbances; adjust dose to avoid dehydration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gout: Asymptomatic hyperuricemia may occur and gout may be precipitated (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gynecomastia: Related to dose and duration of therapy; typically is reversible following discontinuation of therapy but may persist (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperkalemia: Hyperkalemia may occur; risk of hyperkalemia is increased with renal impairment, excessive potassium intake, and patients taking certain drugs (eg, ACE inhibitors, angiotensin-II blockers, NSAIDs). Monitor closely for hyperkalemia; increases in serum potassium are dose related and rates of hyperkalemia also increase with declining renal function. The concurrent use of larger doses of ACE inhibitors (eg, &ge; lisinopril 10 mg daily in adults) also increases the risk of hyperkalemia (ACCF/AHA [Yancy 2013]). Dose reduction or interruption of therapy may be necessary with development of hyperkalemia. Use is contraindicated in patients with hyperkalemia; use caution in conditions known to cause hyperkalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumorigenic: <b>[US Boxed Warning]: Shown to be a tumorigen in chronic toxicity animal studies. Avoid unnecessary use.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal vein catheterization: Discontinue use prior to adrenal vein catheterization.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: When evaluating a heart failure patient for spironolactone treatment, eGFR should be &gt;30 mL/minute/1.73 m<sup>2</sup> or creatinine should be &le;2.5 mg/dL (men) or &le;2 mg/dL (women) with no recent worsening and potassium &lt;5 mEq/L with no history of severe hyperkalemia (ACCF/AHA [Yancy 2013]). Serum potassium levels require close monitoring and management if elevated. The manufacturer of the tablet recommends to discontinue or interrupt therapy if serum potassium &gt;5 mEq/L or serum creatinine &gt;4 mg/dL. The ACCF/AHA recommends considering discontinuation upon the development of serum potassium &gt;5.5 mEq/L or worsening renal function with careful evaluation of the entire medical regimen. Avoid routine triple therapy with the combined use of an ACE inhibitor, ARB, and spironolactone. Instruct patients with heart failure to discontinue use during an episode of diarrhea or dehydration or when loop diuretic therapy is interrupted (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; minor alterations of fluid and electrolyte balance may precipitate hepatic coma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Risk of hyperkalemia is increased with declining renal function and with the concurrent use of larger doses of ACE inhibitors (eg, &ge; lisinopril 10 mg daily in adults) (ACCF/AHA [Yancy 2013]). Use with caution in patients with mild renal impairment; tablets are contraindicated with anuria, acute renal insufficiency, or significant impairment of renal excretory function.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Avoid use of tablets &gt;25 mg/day in elderly patients with heart failure or with reduced renal function (eg, CrCl &lt;30 mL/minute or eGFR &le;30 mL/minute/1.73 m<sup>2</sup> [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Other warnings/precautions</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suspension: Suspension is <b>NOT</b> therapeutically equivalent to tablets. In patients requiring &gt;100 mg/dose, use tablets (&gt;100 mg/dose of suspension may result in spironolactone concentration higher than expected).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300079\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222828\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9943&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: Spironolactone may diminish the therapeutic effect of Abiraterone Acetate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists: Spironolactone may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AMILoride: May enhance the hyperkalemic effect of Spironolactone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: Potassium-Sparing Diuretics may enhance the adverse/toxic effect of Ammonium Chloride. Specifically the risk of systemic acidosis. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtorvaSTATin: May enhance the adverse/toxic effect of Spironolactone. Specifically, there is a theoretical potential for enhanced effects on reducing endogenous steroid activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Canagliflozin may enhance the hypotensive effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Potassium-Sparing Diuretics may diminish the therapeutic effect of Cardiac Glycosides. In particular, the inotropic effects of digoxin appear to be diminished. Potassium-Sparing Diuretics may increase the serum concentration of Cardiac Glycosides. This particular effect may be unique to Spironolactone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholestyramine Resin: May enhance the adverse/toxic effect of Spironolactone. Specifically, the risks of developing metabolic acidosis and hyperkalemia may be elevated with this combination.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): Spironolactone may enhance the arrhythmogenic effect of Ciprofloxacin (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diacerein: May enhance the therapeutic effect of Diuretics. Specifically, the risk for dehydration or hypokalemia may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Spironolactone may increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Drospirenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium-Sparing Diuretics. Management: Monitor serum potassium concentrations closely. The spironolactone Canadian product monograph lists its combination with heparin or low molecular weight heparins as contraindicated.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: Spironolactone may diminish the therapeutic effect of Mitotane.  Management: Consideration should be given to discontinuing spironolactone prior to initiating mitotane in order to eliminate the risk of therapeutic failure of the mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Spironolactone may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrofurantoin: May enhance the hyperkalemic effect of Spironolactone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Potassium-Sparing Diuretics. Nonsteroidal Anti-Inflammatory Agents may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Diuretics. Opioid Analgesics may diminish the therapeutic effect of Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Salts: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Potassium-Sparing Diuretics may diminish the therapeutic effect of QuiNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Potassium-Sparing Diuretics may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May enhance the hyperkalemic effect of Potassium-Sparing Diuretics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Triamterene: May enhance the hyperkalemic effect of Spironolactone.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the hyperkalemic effect of Spironolactone.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222856\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food increases the bioavailability of unmetabolized spironolactone by almost 100%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222846\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in some animal reproduction studies. The antiandrogen effects of spironolactone have been shown to cause feminization of the male fetus in animal studies. Spironolactone crosses the placenta (Regitz-Zagrosek 2011).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The treatment of heart failure is generally the same in pregnant and nonpregnant women; however, spironolactone should be avoided in the first trimester due to its antiandrogenic effects (Regitz-Zagrosek 2011). The use of mineralocorticoid receptor antagonists is not recommended to treat chronic uncomplicated hypertension in pregnant women and should generally be avoided in women of reproductive potential. When treatment for hypertension in pregnancy is needed, other agents are preferred (ACOG 2013). Use of diuretics to treat edema during normal pregnancies is not appropriate; use may be considered when edema is due to pathologic causes (as in the nonpregnant patient); monitor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222847\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">The active metabolite of spironolactone (canrenone) has been found in breast milk. Information is available from a case report following maternal use of spironolactone 25 mg twice daily throughout pregnancy, then 4 times daily after delivery. Milk and maternal serum samples were obtained 17 days after birth. Two hours after the maternal dose, canrenone concentrations were ~144 ng/mL (serum) and ~104 ng/mL (milk). When measured 14.5 hours after the dose, canrenone concentrations were ~92 ng/mL (serum) and ~47 ng/mL (milk). The authors calculated the estimated maximum amount of canrenone to the nursing infant to be ~0.2% of the maternal dose (Phelps 1977). Effects to humans are not known; however, this metabolite was found to be carcinogenic in rats. Diuretics have the potential to decrease milk volume and suppress lactation. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother; if use of spironolactone is essential, an alternative method of feeding should be used.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222848\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administration with food increases the bioavailability of spironolactone. Excessive potassium intake (eg, salt substitutes, low-salt foods, bananas, nuts) should be avoided.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222833\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure, serum electrolytes (potassium, sodium), renal function, I &amp; O ratios and daily weight throughout therapy</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">\n      <i>ACCF/AHA heart failure guideline recommendations (ACCF/AHA [Yancy 2013]):</i> Serum potassium and renal function should be checked in 3 days after initiation, at 1 week after initiation, at least monthly for the first 3 months of therapy, and every 3 months thereafter. If adding or increasing the dose of concomitant ACE inhibitors or ARBs, a new cycle of monitoring should be done. If serum potassium increases to &gt;5.5 mEq/L or renal function worsens, hold doses until potassium is &lt;5 mEq/L and consider restarting with a reduced dose after confirming resolution of hyperkalemia/renal insufficiency for at least 72 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222822\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competes with aldosterone for receptor sites in the distal renal tubules, increasing sodium chloride and water excretion while conserving potassium and hydrogen ions; may block the effect of aldosterone on arteriolar smooth muscle as well</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222841\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Suspension results in 15% to 37% higher serum concentration compared to the tablet; doses of suspension &gt;100 mg may result in higher spironolactone concentrations than expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Tablet: 2 to 3 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: High-fat/-calorie meal increased the bioavailability of spironolactone ~90%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Rapid and extensive; hepatic to multiple metabolites, including active metabolites canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: Spironolactone: ~1.4 hours; Canrenone: 16.5 hours (terminal); 7-alpha-spirolactone: 13.8 hours (terminal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Spironolactone: 1 to 2 hours; Canrenone, 7-alpha-spirolactone, and 6-beta-hydroxy-7-alpha: 10 to 35 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet: 2.6 to 4.3 hours (primarily as active metabolites)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Suspension: Spironolactone: 0.5 to 1.5 hours; Canrenone: 2.5 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily as metabolites) and bile (secondary)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222845\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (CaroSpir Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (118 mL): $324.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Aldactone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $304.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $535.37</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $897.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Spironolactone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $45.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $81.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $142.45</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F222849\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aldactin (TW);</li>\n      <li>Aldacton (TR);</li>\n      <li>Aldactone (AE, AT, AU, BB, BD, BE, BF, BH, BJ, BR, CH, CI, CO, CR, CY, CZ, DE, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, HK, HR, HU, IE, IN, IQ, IR, IS, IT, JO, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NL, NO, OM, PA, PE, PH, PK, PL, PT, QA, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SY, TH, TN, TW, TZ, UG, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Aldactone A (AR, BM, BS, BZ, EC, GY, JM, SR, TT, UY);</li>\n      <li>Aldospirone (IL);</li>\n      <li>Aldoxol (PY);</li>\n      <li>Alizar (CL);</li>\n      <li>Alspiron (RO);</li>\n      <li>Altone (TH);</li>\n      <li>Belactone (LK);</li>\n      <li>Diulactone (PH, VN);</li>\n      <li>Flumach (FR);</li>\n      <li>Huma-Spiroton (HU);</li>\n      <li>Hyles (TH);</li>\n      <li>Indurit (PY);</li>\n      <li>Lactone (PH);</li>\n      <li>Noractone (AE, JO, QA);</li>\n      <li>Osiren (AT);</li>\n      <li>Osyrol (DE, JP);</li>\n      <li>Pondactone (TH);</li>\n      <li>S-Tone (TH);</li>\n      <li>Skyton (TW);</li>\n      <li>Spilac (LK);</li>\n      <li>Spinolac (VN);</li>\n      <li>Spiractin (AU, ZA);</li>\n      <li>Spiretic (BD);</li>\n      <li>Spirix (DK, FI, NO);</li>\n      <li>Spiroctan (FR, LU);</li>\n      <li>Spirofar (PH);</li>\n      <li>Spirola (ID);</li>\n      <li>Spirolacton (ID);</li>\n      <li>Spirolon (BF, BJ, CI, EC, ET, GH, GM, GN, KE, LR, MA, ML, MR, MT, MU, MW, MY, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);</li>\n      <li>Spiron (DK, HU);</li>\n      <li>Spirone (PE);</li>\n      <li>Spirono-Isis (DE);</li>\n      <li>Spironol (IL);</li>\n      <li>Spironolacton-ratiopharm (LU);</li>\n      <li>Spironolactone-Eurogenerics (LU);</li>\n      <li>Spironolactone-Searle (LU);</li>\n      <li>Spirotone (NZ, TW);</li>\n      <li>Unilactone (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Uractone (LU);</li>\n      <li>Uractonum (SG, TR);</li>\n      <li>Veroshpiron (UA);</li>\n      <li>Verospiron (BD, BG, CZ, EE, HN, HU, LT, SK);</li>\n      <li>Vivitar (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Xenalon Lactabs (DO)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aldactone (spironolactone) [prescribing information]. New York, NY: Pfizer Inc; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aldactone (spironolactone) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; July 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131. doi: 10.1097/01.AOG.0000437382.03963.88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/24150027/pubmed\" target=\"_blank\" id=\"24150027\">24150027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. <i>J Am Coll Cardiol</i>. 2011;57(20):2037-2114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/21524875/pubmed\" target=\"_blank\" id=\"21524875\">21524875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bozkurt B, Agoston I, and Knowlton AA, &ldquo;Complications of Inappropriate Use of Spironolactone in Heart Failure: When an Old Medicine Spirals Out of New Guidelines,&rdquo; <i>J Am Coll Cardiol</i>, 2003, 41(2):211-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12535810/pubmed\" target=\"_blank\" id=\"12535810\">12535810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carospir (spironolactone) [prescribing information]. Farmville, NC: CMP Pharma; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6235834\"></a>Goodfellow A, Alaghband-Zadeh J, Carter G, et al. Oral spironolactone improves acne vulgaris and reduces sebum excretion. <i>Br J Dermatol</i>. 1984;111(2):209-214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/6235834/pubmed\" target=\"_blank\" id=\"6235834\">6235834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hunter MH and Carek PJ, &ldquo;Evaluation and Treatment of Women With Hirsutism,&rdquo; <i>Am Fam Physician</i>, 2003, 67(12):2565-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12825846/pubmed\" target=\"_blank\" id=\"12825846\">12825846</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juurlink DN, Mamdani MM, Lee DS, et al, &ldquo;Rates of Hyperkalemia After Publication of the Randomized Aldactone Evaluation Study,&rdquo; <i>N Engl J Med</i>, 2004, 351(6):543-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/15295047/pubmed\" target=\"_blank\" id=\"15295047\">15295047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17980017\"></a>Koulouri O and Conway GS, &ldquo;A Systematic Review of Commonly Used Medical Treatments for Hirsutism in Women,&rdquo; <i>Clin Endocrinol</i>, 2008, 68(5): 800-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/17980017/pubmed\" target=\"_blank\" id=\"17980017\">17980017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18252793\"></a>Martin KA, Chang RJ, Ehrmann DA, et al, &ldquo;Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline,&rdquo; <i>J Clin Endocrinol Metab</i>, 2008, 93(4):1105-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/18252793/pubmed\" target=\"_blank\" id=\"18252793\">18252793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2943311\"></a>Muhlemann MF, Carter GD, Cream JJ, et al. Oral spironolactone: an effective treatment for acne vulgaris in women. <i>Br J Dermatol</i>. 1986;115(2):227-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/2943311/pubmed\" target=\"_blank\" id=\"2943311\">2943311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. <i>Hypertension</i>. 2002;40(6):897-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12468576/pubmed\" target=\"_blank\" id=\"12468576\">12468576</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, &quot;The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,&rdquo; <i>Pediatrics</i>, 2004, 114(2 Suppl 4th Report):555-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/15286277/pubmed\" target=\"_blank\" id=\"15286277\">15286277</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23247304\"></a>O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481.] <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palmer BF, &ldquo;Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System,&rdquo; <i>N Engl J Med</i>, 2004, 351:585-92.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/15295051/pubmed\" target=\"_blank\" id=\"15295051\">15295051</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phelps DL, Karim A. Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk. <i>J Pharm Sci</i>. 1977;66(8):1203.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/894512/pubmed\" target=\"_blank\" id=\"894512\">894512</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. <i>N Engl J Med</i>. 2003;348(14):1309-1321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12668699/pubmed\" target=\"_blank\" id=\"12668699\">12668699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pitt B, Zannad F, Remme WJ, et al, &ldquo;The Effect of Spironolactone on Morbidity and Mortality in Patients With Severe Heart Failure. Randomized Aldactone Evaluation Study Investigators,&rdquo; <i>N Engl J Med</i>, 1999, 341(10):709-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/10471456/pubmed\" target=\"_blank\" id=\"10471456\">10471456</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy,&rdquo; <i>Am J Obstet Gynecol</i>, 2000, 183(1):S1-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/10920346/pubmed\" target=\"_blank\" id=\"10920346\">10920346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA; American Association for the Study of Liver Diseases. Practice guideline: management of adult patients with ascites due to cirrhosis: update 2012. http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf. Accessed May 6, 2015.23463403</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Runyon BA. Management of adult patients with ascites due to cirrhosis: update 2012. Hepatology. 2013:1-27. http://www.aasld.org/practiceguidelines/Documents/ascitesupdate2013.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaw JC, &ldquo;Acne: Effect of Hormones on Pathogenesis and Management,&rdquo; <i>Am J Clin Dermatol</i>, 2002, 3(8):571-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12358558/pubmed\" target=\"_blank\" id=\"12358558\">12358558</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Skluth HA and Gums JG. Spironolactone: a re-examination. <i>DICP</i>. 1990;24(1):52-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/2405587/pubmed\" target=\"_blank\" id=\"2405587\">2405587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo; <i>Circulation</i>, 2011, 124(22):2458-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/22052934/pubmed\" target=\"_blank\" id=\"22052934\">22052934</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thiboutot D and Chen W, &ldquo;Update and Future of Hormonal Therapy in Acne,&rdquo; <i>Dermatology</i>, 2003, 206(1):57-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/12566806/pubmed\" target=\"_blank\" id=\"12566806\">12566806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    V&aacute;clav&iacute;k J, Sedl&aacute;k R, Jarkovsk&yacute; J, Koci&aacute;nov&aacute; E, T&aacute;borsk&yacute; M. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). <i>Medicine (Baltimore)</i>. 2014;93(27):e162. doi: 10.1097/MD.0000000000000162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/25501057/pubmed\" target=\"_blank\" id=\"25501057\">25501057</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi: 10.1111/jch.12237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Williams B, MacDonald TM, Morant S, et al; British Hypertension Society's PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. <i>Lancet</i>. 2015:S0140-6736(15)00257-3<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/26414968/pubmed\" target=\"_blank\" id=\"26414968\">26414968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published online May 20, 2016]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/27208050/pubmed\" target=\"_blank\" id=\"27208050\">27208050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/spironolactone-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf. Accessed May 17, 2016.26897386</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9943 Version 218.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709416\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F222861\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F222862\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F222908\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F222866\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F222886\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F222867\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F222868\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F21885517\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F222835\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F222819\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F50591704\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132823\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F222838\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25471214\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F222916\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F222826\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F222842\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F222823\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300079\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F222828\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F222856\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F222846\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F222847\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F222848\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F222833\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F222822\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F222841\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F222845\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F222849\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9943|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=spironolactone-patient-drug-information\" class=\"drug drug_patient\">Spironolactone: Patient drug information</a></li><li><a href=\"topic.htm?path=spironolactone-pediatric-drug-information\" class=\"drug drug_pediatric\">Spironolactone: Pediatric drug information</a></li></ul></div></div>","javascript":null}